PTAB designates seven IPR decisions as “informative”

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

PTAB designates seven IPR decisions as “informative”

ptab-web-icon.jpg

The Patent Trial and Appeal Board has designated seven of its decisions rendered in inter partes review (IPR) proceedings as “informative”

uspto.jpg

In each decision, the PTAB denied institution of an IPR under 35 USC § 325(d), which permits the Director to take into account whether, and reject the petition or request because, the same or substantially the same prior art or arguments previously were presented.

The seven decisions are:

Medtronic, Inc v Nuvasive Inc., Paper 8, No. IPR2014-00487 (September 11 2014)

Unified Patents Inc v PersonalWeb Techs., LLC, Paper 13, No. IPR2014-00702 (July 24 2014)

Prism Pharma Co v Choongwae Pharma Corp., Paper 14, No. IPR2014-00315 (July 8 2014)

Unilever, Inc v Procter & Gamble Co., Paper 17, No. IPR2014-00506 (July 7 2014)

Medtronic, Inc v Robert Bosch Healthcare Systems, Inc., Paper 17, No. IPR2014-00436 (June 19 2014)

Intelligent Bio-Systems Inc. v Illumina Cambridge Limited, Paper 19, No. IPR2013-00324 (November 21 2013)

ZTE Corp v ContentGuard Holdings, Inc., Paper 12, No. IPR2013-00454 (25 September 25 2013)

Decisions designated as "informative" can be viewed here.


more from across site and SHARED ros bottom lb

More from across our site

Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Six hires across the IP spectrum reflect Orrick’s efforts to better serve tech clients across the IP lifecycle
David Stone, partner at White & Case, argues that the government’s planned reforms will modernise and futureproof UK design law, but leave two of the thorniest problems unresolved
Max Scott will join the firm’s IP transactions group in California, becoming the latest Weil IP partner to secure their future
Yonatan Drori, attorney at Drori-Stav IP in Israel, explains why foreign counsel must treat Israel’s patent disclosure requirements as an ongoing obligation, rather than a one-off formality
From Japan to Southeast Asia, domestic and regional firms picked up some of the biggest prizes, while key foreign players maintained momentum
Earlier this month, Managing IP had exclusively reported that the French arm of Taylor Wessing was minded to pull out of the deal
Gift this article